Effects of pravastatin on serum adiponectin levels in female patients with type 2 diabetes mellitus

Atherosclerosis

Volumn 227, Issue 2, 2013, Pages 355-359

  Kim, Ji Hyun ^a   Lee, Ma Rie ^a   Shin, Jung Ah ^a   Lee, Sung Soo ^a   Lee, Jung Min ^a   You, Soon Jib ^a   Yoon, Kun Ho ^a   Chang, Sang Ah ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

Adiponectin; Diabetes mellitus; Pravastatin

Indexed keywords

ADIPONECTIN; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PRAVASTATIN;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HOMEOSTASIS MODEL ASSESSMENT OF INSULIN RESISTANCE; HUMAN; HYPERCHOLESTEROLEMIA; INSULIN SENSITIVITY; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL;

ADIPONECTIN; ADULT; AGED; BODY MASS INDEX; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; LIPIDS; MIDDLE AGED; PRAVASTATIN;

EID: 84875051822     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2013.01.045     Document Type: Article

References (30)

1. Kadowaki T., Yamauchi T., Kubota N., Hara K., Ueki K., Tobe K. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 2006, 116:1784-1792.
2. von Eynatten M., Schneider J.G., Humpert P.M., et al. Serum adiponectin levels are an independent predictor of the extent of coronary artery disease in men. J Am Coll Cardiol 2006, 47:2124-2126.
3. Tsao T.S., Murrey H.E., Hug C., Lee D.H., Lodish H.F. Oligomerization state-dependent activation of NF-kappa B signaling pathway by adipocyte complement-related protein of 30 kDa (Acrp30). J Biol Chem 2002, 277:29359-29362.
4. Hara K., Horikoshi M., Yamauchi T., et al. Measurement of the high-molecular weight form of adiponectin in plasma is useful for the prediction of insulin resistance and metabolic syndrome. Diabetes Care 2006, 29:1357-1362.
5. Kobayashi H., Ouchi N., Kihara S., et al. Selective suppression of endothelial cell apoptosis by the high molecular weight form of adiponectin. Circ Res 2004, 94:e27-31.
6. Inoue T., Kotooka N., Morooka T., et al. High molecular weight adiponectin as a predictor of long-term clinical outcome in patients with coronary artery disease. Am J Cardiol 2007, 100:569-574.
7. Koh K.K., Quon M.J., Han S.H., et al. Differential metabolic effects of pravastatin and simvastatin in hypercholesterolemic patients. Atherosclerosis 2009, 204:483-490.
8. Kai T., Arima S., Taniyama Y., Nakabou M., Kanamasa K. Comparison of the effect of lipophilic and hydrophilic statins on serum adiponectin levels in patients with mild hypertension and dyslipidemia: Kinki Adiponectin Interventional (KAI) Study. Clin Exp Hypertens 2008, 30:530-540.
9. Yokoyama H., Saito S., Daitoku K., et al. Effects of pravastatin and rosuvastatin on the generation of adiponectin in the visceral adipose tissue in patients with coronary artery disease. Fundam Clin Pharmacol 2011, 25:378-387.
10. Nezu U., Tsunoda S., Yoshimura H., et al. Pravastatin potentiates increases in serum adiponectin concentration in dyslipidemic patients receiving thiazolidinedione: the DOLPHIN study. J Atheroscler Thromb 2010, 17:1063-1069.
11. Sugiyama S., Fukushima H., Kugiyama K., et al. Pravastatin improved glucose metabolism associated with increasing plasma adiponectin in patients with impaired glucose tolerance and coronary artery disease. Atherosclerosis 2007, 194:e43-51.
12. Saito S., Fujiwara T., Matsunaga T., et al. Increased adiponectin synthesis in the visceral adipose tissue in men with coronary artery disease treated with pravastatin: a role of the attenuation of oxidative stress. Atherosclerosis 2008, 199:378-383.
13. Gannagé-Yared M.H., Azar R.R., Amm-Azar M., et al. Pravastatin does not affect insulin sensitivity and adipocytokines levels in healthy nondiabetic patients. Metabolism 2005, 54:947-951.
14. Ando H., Sugimoto K., Yanagihara H., et al. Effects of atorvastatin and pravastatin on glucose tolerance, adipokine levels and inflammatory markers in hypercholesterolaemic patients. Clin Exp Pharmacol Physiol 2008, 35:1012-1017.
15. Mita T., Watada H., Nakayama S., et al. Preferable effect of pravastatin compared to atorvastatin on beta cell function in Japanese early-state type 2 diabetes with hypercholesterolemia. Endocr J 2007, 54:441-447.
16. van Hoek M., van Tol A., van Vark-van der Zee L.C., et al. Role of plasma adiponectin on the HDL-cholesterol raising effect of atorvastatin in patients with type 2 diabetes. Curr Med Res Opin 2009, 25:93-101.
17. Bellia A., Rizza S., Galli A., et al. Early vascular and metabolic effects of rosuvastatin compared with simvastatin in patients with type 2 diabetes. Atherosclerosis 2010, 210:199-201.
18. Takebayashi K., Suetsugu M., Matsumoto S., Aso Y., Inukai T. Effects of rosuvastatin and colestimide on metabolic parameters and urinary monocyte chemoattractant protein-1 in type 2 diabetic patients with hyperlipidemia. South Med J 2009, 102:361-368.
19. Chu C.S., Lee K.T., Lee M.Y., et al. Effects of rosiglitazone alone and in combination with atorvastatin on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Am J Cardiol 2006, 97:646-650.
20. Weyer C., Funahashi T., Tanaka S., et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001, 86:1930-1935.
21. Basu R., Pajvani U.B., Rizza R.A., Scherer P.E. Selective downregulation of the high molecular weight form of adiponectin in hyperinsulinemia and in type 2 diabetes: differential regulation from nondiabetic subjects. Diabetes 2007, 56:2174-2177.
22. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1997, 20:1183-1197.
23. Saltevo J., Kautiainen H., Vanhala M. Gender differences in adiponectin and low-grade inflammation among individuals with normal glucose tolerance, prediabetes, and type 2 diabetes. Gend Med 2009, 6:463-470.
24. Baker W.L., Talati R., White C.M., Coleman C.I. Differing effect of statins on insulin sensitivity in non-diabetics: a systemic review and metanalysis. Diabetes Res Clin Pract 2010, 87:98-107.
25. Kostapanos M.S., Liamis G.L., Milionis H.J., Elisaf M.S. Do statins beneficially or adversely affect glucose homeostasis?. Curr Vasc Pharmacol 2010, 8:612-631.
26. Chamberlain L.H. Inhibition of isoprenoid biosynthesis causes insulin resistance in 3T3-L1 adipocytes. FEBS Lett 2001, 507:357-361.
27. Nakata M., Nagasaka S., Kusaka I., Matsuoka H., Ishibashi S., Yada T. Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycaemic control. Diabetologia 2006, 49:1881-1892.
28. Takaguri A., Satoh K., Itagaki M., Tokumitsu Y., Ichihara K. Effects of atorvastatin and pravastatin on signal transduction related to glucose uptake in 3T3L1 adipocytes. J Pharmacol Sci 2008, 107:80-89.
29. Cannon C.P., Braunwald E., McCabe C.H., et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004, 350:1495-1504.
30. Thorand B., Baumert J., Döring A., for the KORA Group, et al. Sex differences in the relation of body composition to markers of inflammation. Atherosclerosis 2006, 184:216-224.